NEXI Live signals | Maximize Profits with Getagraph.com

SELL 122136 min ago

@ $9.74

Issued: 8 Feb 2024 @ 15:22

Return: -66.77%

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 11:58):

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases...

Stats
Today's Volume	11 816.00
Average Volume	80 130.00
Market Cap	4.44M
EPS	$0 ( 2024-04-11 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.110
ATR14	$0.0180 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Marchio Albert N Ii	Buy	0
2023-11-21	Roemer Alan S.	Sell	3 833	Common Stock
2023-11-22	Roemer Alan S.	Sell	3 992	Common Stock
2023-08-30	Stover Timothy	Sell	0	Common Stock
2023-08-30	Stover Timothy	Sell	6 375	Stock Option (right to buy)

INSIDER POWER
28.27
Last 99 transactions
Buy: 3 627 952 \| Sell: 1 972 123

NexImmune, Inc. Common Correlation

10 Most Positive Correlations

10 Most Negative Correlations
GOODM	-0.854

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NexImmune, Inc. Common Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.02M (0.00 %)
EPS:	$-30.82

FY	2023
Revenue:	$0
Gross Profit:	$-1.02M (0.00 %)
EPS:	$-30.82

FY	2022
Revenue:	$0
Gross Profit:	$-1.50M (0.00 %)
EPS:	$534.29

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.25

Financial Reports:

No articles found.

NexImmune, Inc. Common

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.